{"id":"NCT00345683","sponsor":"GlaxoSmithKline","briefTitle":"Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.","officialTitle":"Single-blind, Randomized, Controlled, Multinational Study for the Evaluation of Safety of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to Monovalent Hib Control Vaccine in Healthy Infants at 2, 4, 6, and 12 to 15 Months of Age.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-07","primaryCompletion":"2008-09","completion":"2008-11","firstPosted":"2006-06-28","resultsPosted":"2012-07-20","lastUpdate":"2016-11-29"},"enrollment":4021,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"PREVENTION"},"conditions":["Haemophilus Influenzae Type b","Neisseria Meningitidis"],"interventions":[{"type":"BIOLOGICAL","name":"GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (792014)","otherNames":[]},{"type":"BIOLOGICAL","name":"PedvaxHIB","otherNames":["Monovalent Hib conjugate vaccine."]},{"type":"BIOLOGICAL","name":"Prevnar","otherNames":[]},{"type":"BIOLOGICAL","name":"M-M-R II","otherNames":["Measles","mumps and rubella vaccine."]},{"type":"BIOLOGICAL","name":"Varivax","otherNames":["Varicella vaccine"]}],"arms":[{"label":"Menhibrix Group","type":"EXPERIMENTAL"},{"label":"ActHIB Group","type":"ACTIVE_COMPARATOR"}],"summary":"The booster phase of the study will evaluate the safety of Hib-MenCY-TT vaccine compared to a control group receiving licensed Hib conjugate vaccine at 12 to 15 months of age.\n\nThis protocol posting deals with objectives \\& outcome measures of the booster phase. The objectives \\& outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00345579).\n\nNo new recruitment will take place during this booster phase of the study. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.","primaryOutcome":{"measure":"Number of Subjects Reporting Serious Adverse Events (SAEs)","timeFrame":"From fourth dose up to Day 30 after fourth dose vaccination (from study Month 10-13 up to study Month 11-14)","effectByArm":[{"arm":"Menhibrix Group","deltaMin":12,"sd":null},{"arm":"ActHIB Group","deltaMin":1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":1,"exclusionCount":9},"locations":{"siteCount":57,"countries":["United States","Mexico"]},"refs":{"pmids":["22327493"],"seeAlso":["http://www.clinicaltrials.gov/ct/show/NCT00345579"]},"adverseEventsSummary":{"seriousAny":{"events":72,"n":3010},"commonTop":[]}}